article thumbnail

AbbVie exploring how CRISPR gene editing can improve cell therapies

Bio Pharma Dive

Using technology from Caribou Biosciences, AbbVie hopes to engineer "off-the-shelf" CAR-T cells that can better withstand attacks from the immune system.

article thumbnail

Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline

Bio Pharma Dive

The CRISPR biotech raised $115 million in a Series C financing aimed at advancing its engineered cell therapy research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene editing: beyond the hype

pharmaphorum

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers. That would just slow the whole field down.

article thumbnail

Moderna partners with Life Edit for mRNA gene editing therapies

Pharmaceutical Technology

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. The post Moderna partners with Life Edit for mRNA gene editing therapies appeared first on Pharmaceutical Technology.

article thumbnail

Asklepios partners with ReCode on gene-editing platform

Pharmaceutical Technology

Asklepios BioPharmaceutical has entered a research partnership and option agreement with ReCode Therapeutics for exploring its single-vector gene-editing platform. The new solution will enable complete gene insertion by delivering the gene-editing tool and DNA as mixed cargo to desired targets in one LNP.

article thumbnail

ElevateBio and Affini-T collaborate to develop T cell therapies

Pharmaceutical Technology

ElevateBio has entered a partnership with Affini-T Therapeutics to progress the latter’s engineered TCR-T therapies focused on Kirsten rat sarcoma viral oncogene homolog (KRAS), a dominant oncogenic driver mutation in solid tumours.

article thumbnail

Trends in next-generation delivery technologies to advance gene-modified cell therapies

Pharmaceutical Technology

Lipid nanoparticles are enabling a new generation of engineered cell therapies with a push towards more complex cell engineering and gene editing for allogeneic therapies